These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30061386)

  • 21. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Kwong PD; Doyle ML; Casper DJ; Cicala C; Leavitt SA; Majeed S; Steenbeke TD; Venturi M; Chaiken I; Fung M; Katinger H; Parren PW; Robinson J; Van Ryk D; Wang L; Burton DR; Freire E; Wyatt R; Sodroski J; Hendrickson WA; Arthos J
    Nature; 2002 Dec; 420(6916):678-82. PubMed ID: 12478295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles.
    Lusvarghi S; Lohith K; Morin-Leisk J; Ghirlando R; Hinshaw JE; Bewley CA
    ACS Infect Dis; 2016 Nov; 2(11):882-891. PubMed ID: 27669574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A solution NMR study of the interactions of oligomannosides and the anti-HIV-1 2G12 antibody reveals distinct binding modes for branched ligands.
    Enríquez-Navas PM; Marradi M; Padro D; Angulo J; Penadés S
    Chemistry; 2011 Feb; 17(5):1547-60. PubMed ID: 21268157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transgenic plant production of Cyanovirin-N, an HIV microbicide.
    Sexton A; Drake PM; Mahmood N; Harman SJ; Shattock RJ; Ma JK
    FASEB J; 2006 Feb; 20(2):356-8. PubMed ID: 16354721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.
    Férir G; Huskens D; Palmer KE; Boudreaux DM; Swanson MD; Markovitz DM; Balzarini J; Schols D
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1513-23. PubMed ID: 22607556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of elastin-like peptide fusions on the quantity and quality of a tobacco-derived human immunodeficiency virus-neutralizing antibody.
    Floss DM; Sack M; Arcalis E; Stadlmann J; Quendler H; Rademacher T; Stoger E; Scheller J; Fischer R; Conrad U
    Plant Biotechnol J; 2009 Dec; 7(9):899-913. PubMed ID: 19843249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of "Purple Endosperm Rice" by Engineering Anthocyanin Biosynthesis in the Endosperm with a High-Efficiency Transgene Stacking System.
    Zhu Q; Yu S; Zeng D; Liu H; Wang H; Yang Z; Xie X; Shen R; Tan J; Li H; Zhao X; Zhang Q; Chen Y; Guo J; Chen L; Liu YG
    Mol Plant; 2017 Jul; 10(7):918-929. PubMed ID: 28666688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
    Pantophlet R; Wilson IA; Burton DR
    Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.
    Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A
    J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.
    Major JG; Liou RS; Sun LK; Yu LM; Starnes SM; Fung MS; Chang TW; Chang NT
    Hum Antibodies Hybridomas; 1994; 5(1-2):9-17. PubMed ID: 7858187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
    Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
    J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
    Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
    Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.